The global pharma industry, to meet the demands of a fast evolving marketplace and the shift from product to patient outcomes, needs to radically overhaul its supply chains, according to a new report from PwC.
Widely considered the back bone of a pharma company, many of today’s supply chains are worryingly ill equipped to cope with the industry’s future needs. Most companies have asset bases unable to produce the sort of therapies now in the pipeline with more complex manufacturing and distribution processes, different supply chains for a range of products and shorter product lifecycles. The growing importance of emerging markets, new modes of healthcare delivery, live licensing developments and environmental concerns, are all placing pressure on current pharma supply chain models with the risk that many will break.
As a result PwC believes that over the next decade, many companies will be required to strategically reassess and radically change their manufacturing and distribution model . In fact, according to the PwC report, titled, ‘Pharma 2020: Supplying the future. Which path will you take?’ change in the industry’s remit has even more fundamental implications for supply chains. Over the next ten years, pharma companies will increasingly have to manage a vast network of service providers, as well as manufacturing and distributing their own products.
By 2020, the management of information transfer between the pharma company, the patient and healthcare provider will be as important as the movement of products. Supply chains must therefore evolve so as to direct and manage this shift, and companies will need to acquire a much deeper understanding of patients and their healthcare needs.
Simon Friend, global pharmaceutical and life sciences leader, PwC, commented:
“In a world where outcomes now count for everything, the ability to integrate data, products and services in a coherent business offering that delivers increased value and better understands the needs of the patient is vital. Companies must now work hard to get closer to their patients as by 2020, there is little doubt that the data behind a product will as valuable as the product itself.”
The global pharma industry will therefore, need to develop different supply chain models for different product types and patient segments, learn to use their supply chains as a means of market differentiation, all while recognising the importance of information over product.
Steve Arlington, global advisory pharmaceutical and life sciences leader, PwC, concluded: “The most successful pharma companies will be those that now recognise the underlying value locked in their supply chain and can leverage it as a value and brand differentiator rather than just a cost. Those that recognise information is the currency of the future, will be those that go the final mile and stand out by 2020.”
1. Health reform shifts emphasis from product features to patient outcomes: The government's emphasis on health outcomes as a basis for payments will require pharmaceutical companies to not only manage the manufacturing and distribution of medicines and companion diagnostics, but also to combine product offerings with data and supplemental services that add value through improved outcomes and efficiencies.
2. New products types: The growth of biologics, bioengineered vaccines and advancements such as stem cell research and nanotechnology are diversifying pharma's portfolio with products that have a shorter shelf life and require more complex manufacturing and distribution processes than shelf-stable pills and conventional medicines.
3. Incremental product launch alters the sales curve: Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have shown interest in limited label approvals, granting "live licenses" contingent on ongoing testing versus the all-or-nothing phase I through IV approach. Current processes support revenue projections for "big bang" product launches, with peak sales upfront. Pharma companies will need more adaptable cost structures that preserve gross margins at each stage of the product lifecycle.
4. New modes of healthcare delivery: Greater use of electronic health records, e-prescribing, mobile health applications and remote monitoring are moving healthcare delivery, including medication management, beyond hospitals and physicians offices into homes, communities and direct to patients. Pharmaceutical companies will need real-time information to manage wider distribution networks and demand-driven manufacturing and distribution processes.
5. Growing importance of emerging markets: The growing importance of the emerging markets will require pharmaceutical companies to understand patient needs and preferences in the developing world and modify cost and design of product offerings and services accordingly.
6. Greater public scrutiny: Globalization, the foreign sourcing and manufacture of regulated products, and an increase in the volume and complexity of imported products have increased the need for supply chain control to identify the risk of contamination and fake medicines. Regulators are raising the bar on supply chain safety, demanding sophisticated technology solutions to track and trace product throughout the supply chain.
"The current pharmaceutical supply chain worked well when the 'blockbuster' paradigm prevailed, but pharma's focus in a post-health reform world is shifting from products to patients, and their supply chain processes need to adopt the speed and agility of other, more consumer-oriented industries such as consumer electronics and mass retailing," said Wynn Bailey, head of supply chain strategies, PwC. "In a world where outcomes count for everything, health organizations need to acquire a much deeper understanding of patients and their healthcare needs. Information is the new currency, and the data behind the product may soon be as valuable as the product itself."
PwC predicts that the pharmaceutical supply chain will undergo three key changes over the next decade. It will become fragmented, with different models for different product types and patient segments; It will become a means of market differentiation and source of economic value; and It will become a two-way street, with information flowing upstream to drive the downstream flow of products and services, and the management of information transferred between the pharma company, the patient and healthcare provider will become as important as the movement of product.
"The most successful pharma companies will be those that recognize the underlying value locked in their supply chain and can leverage it as a value and brand differentiator rather than just a cost," said Steve Arlington, global advisory pharmaceutical and life sciences leader, PwC. "Companies that recognize information is the currency of the future, will be those that go the final mile and stand out by 2020."
In its report, PwC outlines four potential scenarios that pharmaceutical companies might explore as a way to restructure their supply chains. Depending on their product and channel portfolio, most companies will have to manage to more than one scenario simultaneously.
Companies that concentrate on specialist therapies might exit from manufacturing altogether and, instead, become a virtual manufacturer, outsourcing the entire supply from production of the earliest clinical batches to full-scale manufacturing, packaging and distribution through a network of integrated supply partners. Alternatively, they might position themselves as service innovators, building supply chains that are capable of manufacturing and distributing complex treatments as well as managing multiple suppliers of integrated, valued-added health management services.
Mass-market manufacturers, such as the makers of generic drugs, might position themselves as high-volume, low-cost providers, borrowing lessons in lean manufacturing, strategic pricing and inventory management from the consumer products industry. Another option for mass mass-market manufacturers is to turn their supply chains into profit centers that combine economic manufacturing and distribution of satellite services, such as direct-to-patient delivery, secondary packaging or distribution to hospitals and pharmacies, and then to franchise it as a stand-alone offering for both internal and external customers.
The report provides an in-depth explanation of these scenarios and is available for download at www.pwc.com/pharma2020supplychain. All of the reports in the Pharma 2020 series are available at www.pwc.com/pharma2020.
About PwC's Pharmaceutical and Life Sciences Industry Group
PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group (www.pwc.com/pharma or www.pwc.com/medtech) provides assurance, tax and advisory services to proprietary, generic and specialty drug manufacturers, medical device and instrumentation suppliers, biotechnology companies, wholesalers, pharmacy benefit managers, contract research organizations, and industry associations. The firm is dedicated to delivering effective solutions to the complex strategic, operational, and financial challenges facing pharmaceutical, biotechnology and medical device companies. Follow PwC Health Industries at http://twitter.com/PwCHealth.
About the PwC Network
PwC firms provide industry-focused assurance, tax and advisory services to enhance value for their clients. More than 161,000 people in 154 countries in firms across the PwC network shadre their thinking, experience and solutions to develop fresh perspectives and practical advice. See www.pwc.com for more information.
© 2011 PwC. All rights reserved. "PwC" and "PwC US" refer to PricewaterhouseCoopers LLP, a Delaware limited liability partnership, which is a member firm of PricewaterhouseCoopers International Limited, each member firm of which is a separate legal entity.